BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 16752313)

  • 1. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
    Taupin P
    IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy of severe combined immunodeficiencies.
    Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
    J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow gene therapy for adenosine deaminase deficiency.
    Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
    Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for severe combined immune deficiency.
    Qasim W; Gaspar HB; Thrasher AJ
    Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
    Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
    J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for hematopoietic and immune disorders.
    Kohn DB
    Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S55-8. PubMed ID: 8971410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy.
    Culver KW
    J Insur Med; 1996; 28(2):121-4. PubMed ID: 10163946
    [No Abstract]   [Full Text] [Related]  

  • 16. [Gene therapy for adenosine deaminase (ADA) deficiency: review of the past, the present and the future].
    Ariga T
    Nihon Rinsho; 2001 Jan; 59(1):72-5. PubMed ID: 11197865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on gene therapy for hereditary hematological disorders.
    Herzog RW; Arruda VR
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):215-32. PubMed ID: 15030282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tale of two SCIDs.
    Shaw KL; Kohn DB
    Sci Transl Med; 2011 Aug; 3(97):97ps36. PubMed ID: 21865536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.